GoodRx (NASDAQ:GDRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of GoodRx (NASDAQ:GDRX) from a hold rating to a buy rating in a research note issued to investors on Saturday.

A number of other analysts have also recently commented on GDRX. UBS Group restated a “reduce” rating on shares of GoodRx in a research report on Monday, January 5th. JPMorgan Chase & Co. decreased their target price on shares of GoodRx from $6.00 to $5.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. Barclays started coverage on shares of GoodRx in a research report on Monday, December 8th. They issued an “underweight” rating and a $3.00 price target for the company. Citigroup reduced their price objective on shares of GoodRx from $5.00 to $4.50 and set a “buy” rating for the company in a research note on Friday, January 9th. Finally, Mizuho lowered their target price on shares of GoodRx from $5.00 to $4.00 and set a “neutral” rating on the stock in a research note on Thursday, November 6th. Five investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, GoodRx has an average rating of “Hold” and an average target price of $4.91.

GoodRx Price Performance

NASDAQ GDRX opened at $2.68 on Friday. GoodRx has a 52 week low of $2.61 and a 52 week high of $5.81. The firm has a market capitalization of $909.67 million, a P/E ratio of 29.78, a PEG ratio of 1.02 and a beta of 1.45. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.81. The company has a 50-day moving average price of $2.78 and a 200-day moving average price of $3.72.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Tuesday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a net margin of 3.97% and a return on equity of 9.73%. The business had revenue of $196.03 million for the quarter, compared to the consensus estimate of $195.17 million. During the same quarter last year, the firm posted $0.08 earnings per share. The business’s quarterly revenue was up .4% compared to the same quarter last year. Equities research analysts anticipate that GoodRx will post 0.13 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Quarry LP purchased a new stake in GoodRx in the third quarter valued at approximately $33,000. Boothbay Fund Management LLC acquired a new stake in GoodRx during the 3rd quarter valued at approximately $43,000. Shay Capital LLC purchased a new stake in shares of GoodRx in the 3rd quarter valued at $47,000. Cetera Investment Advisers acquired a new stake in shares of GoodRx in the second quarter worth $50,000. Finally, Walled Lake Planning & Wealth Management LLC purchased a new position in shares of GoodRx during the second quarter worth $55,000. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.